Initial clinical data shows promising results, supporting early evidence of fenofibrate ability to prevent lung damage in Corona patients and reduce COVID-19 severity and mortality even as newly emerging vaccines reduce transmission.
In what has the potential to significantly change how Corona patients are being treated and the severity of the disease, research spearheaded at Jerusalem’s Hebrew University gathered early clinical evidence demonstrating the efficacy of an existing drug in treating COVID-19.
The study, led by Professor Yaakov Nahmias, Director of the Center for Bioengineering at Hebrew University, applied a well-established existing drug to address the buildup of fats in human lung cells caused by the SARS-CoV-2 virus. Initial lab-based results and new data from 1,500 Israel-based Corona patients have been extremely promising and clinical studies are scheduled to begin this week at Barzilai Hospital in Ashkelon, Israel, joining other clinical centers across the United States, South America and Europe.
New drug approved in Europe for uncontrolled COPD. 
